Comparison with the literature
Although this study marks the first comprehensive economic evaluation for this intervention, the findings of it align with those reported in an abstract by Owens19. This US study also found co-amoxiclav prophylaxis to be a dominant strategy ­– even following sensitivity analysis19. Although there are differences in demographics and cost of treatments between the two countries, the alignment of findings further reiterates the prospective role of co-amoxiclav in the prevention of maternal infection.